US Patent

US8735380 — Ulipristal acetate tablets

Formulation · Assigned to Laboratoire HRA Pharma SAS · Expires 2029-02-20 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical tablet formulation of ulipristal acetate with specific excipients in defined weight percentages for oral administration.

USPTO Abstract

The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.

Drugs covered by this patent

Patent Metadata

Patent number
US8735380
Jurisdiction
US
Classification
Formulation
Expires
2029-02-20
Drug substance claim
No
Drug product claim
Yes
Assignee
Laboratoire HRA Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.